Literature DB >> 9418660

Progress in prostate cancer.

P Warde1, M K Gospodarowicz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9418660      PMCID： PMC1228646     

Source DB:  PubMed          Journal:  CMAJ        ISSN： 0820-3946            Impact factor:   8.262


× No keyword cloud information.
  3 in total

1.  Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

Authors:  I F Tannock; D Osoba; M R Stockler; D S Ernst; A J Neville; M J Moore; G R Armitage; J J Wilson; P M Venner; C M Coppin; K C Murphy
Journal:  J Clin Oncol       Date:  1996-06       Impact factor: 44.544

2.  Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin.

Authors:  M Bolla; D Gonzalez; P Warde; J B Dubois; R O Mirimanoff; G Storme; J Bernier; A Kuten; C Sternberg; T Gil; L Collette; M Pierart
Journal:  N Engl J Med       Date:  1997-07-31       Impact factor: 91.245

3.  New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen.

Authors:  F Labrie; A Dupont; A Belanger; L Cusan; Y Lacourciere; G Monfette; J G Laberge; J P Emond; A T Fazekas; J P Raynaud; J M Husson
Journal:  Clin Invest Med       Date:  1982       Impact factor: 0.825
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.